Abstract
It is known that IL-2 cancer immunotherapy is associated with hypotension. The present study was performed to evaluate the influence of low-dose IL-2 subcutaneous therapy on blood pressure in cancer patients with idiopathic hypertension requiring hypotensive therapy. The study included 12 patients, who received IL-2 at 6 million IU/day for at least 4 weeks. Mean values of both systolic and diastolic pressure significantly decreased under IL-2 therapy, and the hypotensive agents were interrupted within 2 weeks in 10/12 patients. Moreover, 6 of them still showed normal blood pressure values without hypotensive therapy after a median follow-up of 6 months. This preliminary study would suggest that low-dose IL-2 subcutaneous therapy may normalize blood pressure values in cancer patients with idiopathic hypertension.
| Original language | English |
|---|---|
| Pages (from-to) | 65-66 |
| Number of pages | 2 |
| Journal | Journal of Biological Regulators and Homeostatic Agents |
| Volume | 8 |
| Issue number | 2 |
| Publication status | Published - 1994 |
Fingerprint
Keywords
- blood pressure
- hypertension
- interleukin-2
ASJC Scopus subject areas
- Agricultural and Biological Sciences(all)
- Endocrinology
- Physiology
- Immunology
- Medicine (miscellaneous)
- Endocrinology, Diabetes and Metabolism
- Physiology (medical)
Cite this
Normalization of idiopathic arterial hypertension following cancer immunotherapy with interleukin-2. / Lissoni, P.; Bastone, A.; Barni, S.; Tancini, G.; Galli, M. A.
In: Journal of Biological Regulators and Homeostatic Agents, Vol. 8, No. 2, 1994, p. 65-66.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Normalization of idiopathic arterial hypertension following cancer immunotherapy with interleukin-2
AU - Lissoni, P.
AU - Bastone, A.
AU - Barni, S.
AU - Tancini, G.
AU - Galli, M. A.
PY - 1994
Y1 - 1994
N2 - It is known that IL-2 cancer immunotherapy is associated with hypotension. The present study was performed to evaluate the influence of low-dose IL-2 subcutaneous therapy on blood pressure in cancer patients with idiopathic hypertension requiring hypotensive therapy. The study included 12 patients, who received IL-2 at 6 million IU/day for at least 4 weeks. Mean values of both systolic and diastolic pressure significantly decreased under IL-2 therapy, and the hypotensive agents were interrupted within 2 weeks in 10/12 patients. Moreover, 6 of them still showed normal blood pressure values without hypotensive therapy after a median follow-up of 6 months. This preliminary study would suggest that low-dose IL-2 subcutaneous therapy may normalize blood pressure values in cancer patients with idiopathic hypertension.
AB - It is known that IL-2 cancer immunotherapy is associated with hypotension. The present study was performed to evaluate the influence of low-dose IL-2 subcutaneous therapy on blood pressure in cancer patients with idiopathic hypertension requiring hypotensive therapy. The study included 12 patients, who received IL-2 at 6 million IU/day for at least 4 weeks. Mean values of both systolic and diastolic pressure significantly decreased under IL-2 therapy, and the hypotensive agents were interrupted within 2 weeks in 10/12 patients. Moreover, 6 of them still showed normal blood pressure values without hypotensive therapy after a median follow-up of 6 months. This preliminary study would suggest that low-dose IL-2 subcutaneous therapy may normalize blood pressure values in cancer patients with idiopathic hypertension.
KW - blood pressure
KW - hypertension
KW - interleukin-2
UR - http://www.scopus.com/inward/record.url?scp=0028046303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028046303&partnerID=8YFLogxK
M3 - Article
C2 - 7863816
AN - SCOPUS:0028046303
VL - 8
SP - 65
EP - 66
JO - Journal of Biological Regulators and Homeostatic Agents
JF - Journal of Biological Regulators and Homeostatic Agents
SN - 0393-974X
IS - 2
ER -